This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read KalVista Pharmaceuticals’s 8K filing here.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Further Reading
- Five stocks we like better than KalVista Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- What is the Australian Securities Exchange (ASX)
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What Are Dividend Champions? How to Invest in the Champions
- Why Amazon Shares May Never Trade Below $200 Again
